- $1.47bn
- $1.58bn
- $418.84m
Brief: Certara Q2 Adjusted EPS USD 0.08 Vs. IBES Estimate USD 0.09
Brief: Certara Announces CFO Transition
NASDAQ RESUMED AT 09:41 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:31 AM
Certara Q1 revenue slightly beats estimates on software demand
Brief: Altasciences And Certara Announce Strategic Partnership To Accelerate Early Drug Development
U.S. STOCKS ON THE MOVE-Tesla, AT&T, Yesway
U.S. STOCKS ON THE MOVE-Certara, Otis, Twilio
Certara rises after up to $135 million sale of regulatory documents business
Brief: Certara Simcyp® Simulator Results Replace Ten Human Trials For Chronic Myeloid Leukemia (Cml) Therapy Asciminib
Certara's Q4 revenue slightly beats as services bookings increase
Brief: Certara Appoints Jon Resnick As Chief Executive Officer
Certara Q3 revenue just misses estimates
Brief: Certara Q3 Adjusted EPS USD 0.14 Vs. IBES Estimate USD 0.11
Brief: Certara Inc - Announces Availability Of Pinnacle 21 Enterprise Plus
AI-driven drug discovery picks up as FDA pushes to reduce animal testing
Certara Inc reports results for the quarter ended June 30 - Earnings Summary
Brief: Certara Q2 Adjusted EPS USD 0.07 Vs. IBES Estimate USD 0.1
Morgan Stanley starts Certara at 'equal weight'